Mirum Pharmaceuticals, Inc. (MIRM) Discusses Topline Results from Phase III AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Transcript
Mirum Pharmaceuticals, Inc. (MIRM) Discusses Topline Results from Phase III AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta - Slideshow (NASDAQ:MIRM) 2026-09-28
Mirum Pharma's Brelovitug Meets Phase 3 Primary Endpoint In AZURE-1 Study For Chronic Hepatitis Delta Virus
Mirum Pharmaceuticals, Inc. (MIRM) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript